We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

60 hedge funds and large institutions have $12M invested in Galectin Therapeutics in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

64% more call options, than puts

Call options by funds: $450K | Put options by funds: $275K

9% more funds holding

Funds holding: 55 → 60 (+5)

0.24% more ownership

Funds ownership: 12.35% → 12.58% (+0.24%)

6% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 16

21% less capital invested

Capital invested by funds: $15.2M → $12M (-$3.14M)

Holders
60
Holders Change
+5
Holders Change %
+9.09%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
15
Reduced
16
Closed
4
Calls
$450K
Puts
$275K
Net Calls
+$175K
Net Calls Change
-$236K

Top Buyers

Rank Fund Capital Flow
1
STA
Summit Trail Advisors
New York
+$46.2K
2
CF
Centaurus Financial
California
+$40.9K
3
Osaic Holdings
Osaic Holdings
Arizona
+$35.6K
4
Wolverine Trading
Wolverine Trading
Illinois
+$31.7K
5
State Street
State Street
Massachusetts
+$29K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$172K
2
Millennium Management
Millennium Management
New York
-$131K
3
Citadel Advisors
Citadel Advisors
Florida
-$84K
4
Morgan Stanley
Morgan Stanley
New York
-$57.7K
5
JF
Jump Financial
Illinois
-$48K
Name Holding Trade Value Shares
Change 		Change in
Stake
HKAM
26
Horizon Kinetics Asset Management
New York
$42K +$3.87K +2,000 +8%
STA
27
Summit Trail Advisors
New York
$38K +$46.2K +23,855 New
Bank of New York Mellon
28
Bank of New York Mellon
New York
$37K – – –
Creative Planning
29
Creative Planning
Kansas
$34K +$19.4K +10,000 +91%
CF
30
Centaurus Financial
California
$34K +$40.9K +21,114 New
Charles Schwab
31
Charles Schwab
California
$29K – – –
WANY
32
Wealthspire Advisors (New York)
New York
$28K +$6.77K +3,500 +25%
Wolverine Trading
33
Wolverine Trading
Illinois
$28K +$31.7K +16,359 New
VF
34
Virtu Financial
New York
$26K -$2.71K -1,402 -8%
VCM
35
Vivaldi Capital Management
Illinois
$23K +$12.4K +6,410 +60%
Neuberger Berman Group
36
Neuberger Berman Group
New York
$22K – – –
BSW
37
Buckingham Strategic Wealth
Missouri
$21K – – –
Simplex Trading
38
Simplex Trading
Illinois
$20K +$16.7K +8,635 +201%
Dimensional Fund Advisors
39
Dimensional Fund Advisors
Texas
$19K – – –
SKK
40
Shepherd Kaplan Krochuk
Massachusetts
$19K – – –
Goldman Sachs
41
Goldman Sachs
New York
$17K -$1.03K -531 -5%
SYBT
42
Stock Yards Bank & Trust
Kentucky
$17K +$20.3K +10,500 New
DAS
43
Dynamic Advisor Solutions
Arizona
$16K – – –
HCM
44
Howard Capital Management
Georgia
$16K +$19.4K +10,000 New
Bank of America
45
Bank of America
North Carolina
$15K +$5.89K +3,044 +46%
Rockefeller Capital Management
46
Rockefeller Capital Management
New York
$14K -$7.74K -4,000 -31%
Wells Fargo
47
Wells Fargo
California
$13K +$2 +1 +0%
MAM
48
Meeder Asset Management
Ohio
$13K +$15.5K +7,994 New
IA
49
IFP Advisors
Florida
$12K – – –
GI
50
Gradient Investments
Minnesota
$6K – – –
1
2
3

GALT Hedge Fund Activity: Q1 2022 in Review

60 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2022, worth a combined $12M — down 21% from $15.2M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new GALT positions and 4 closed out — a net gain of 5 holders — while 15 added to existing stakes and 16 trimmed.

The largest buyer was Summit Trail Advisors, opening a new position worth an estimated $46.2K. The largest seller was Susquehanna International Group, cutting an estimated $172K.

  • 60 institutional investors held Galectin Therapeutics (GALT) as of Q1 2022, up from 55 in Q4 2021.
  • Funds reported $12M of Galectin Therapeutics stock for Q1 2022, down 21% quarter-over-quarter.
  • 9 funds opened new Galectin Therapeutics positions in Q1 2022 and 4 closed out, a net change of +5 holders.
  • The largest Galectin Therapeutics buyer in Q1 2022 was Summit Trail Advisors, an estimated $46.2K added.
  • The largest Galectin Therapeutics seller in Q1 2022 was Susquehanna International Group, an estimated $172K sold.

Based on aggregated 13F filings for Q1 2022.